Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for...

Related Keywords

Hans Vitzthum ,Mary Chen ,Helen Kotanides ,Preclinical Development ,Lifesci Advisors ,Exchange Commission ,Months Of Development Alpha Emitting Therapies ,Astellas Pharma Inc ,Actinium Pharmaceuticals Inc ,Translational Research ,Clinical Development ,Memorial Sloan Kettering Cancer Center ,Actinium Pharmaceuticals ,Targeted Radiopharmaceuticals Summit ,Targeted Radiopharmaceuticals ,Alpha Emitting Therapies ,Next Generation Alpha Emitter Based ,Expert Speaker ,Vice President ,High Dose ,Low Dose Therapeutic Strategy ,Optimizing Treatment ,Antibody Radiation Conjugates ,Bone Marrow Transplant ,Gene Therapy ,Adoptive Cell Therapy ,Elderly Relapsed ,Refractory Acute Myeloid Leukemia ,Memorial Sloan Kettering Cancer ,Antibody Warhead Enabling ,Astellas Pharma ,Looking Statements ,Sci Advisors ,Nc ,